Cipla Q1 FY27 Results Analysis: Margin Compresses 881 bps, PAT Plunges 39%
Cipla Ltd's Q1 FY27 numbers came in soft, with revenue of Rs. 7,119.28 Cr (+2.33% YoY) and PAT growth of -39.19% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | July 23, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 7,119.28 Cr (+2.33% YoY) |
| PAT (Q1) | Rs. 789.05 Cr (-39.19% YoY) |
| EBITDA margin | 16.75% (-881 bps YoY) |
| EPS (Q1) | Rs. 9.77 (-39.20% YoY) |
| Market cap | Rs. 112,593.44 Cr |
| CMP | Rs. 1,393.75 |
Quarter Snapshot
Cipla's Q1 FY27 results show severe margin compression (EBITDA margin down 881 bps YoY to 16.75%) and a 39% PAT decline, driven by material cost inflation, employee cost growth, and US generics headwinds. Revenue grew only 2.33% YoY, with sequential improvement from Q4 trough providing limited comfort. The NPPA contingent liability of Rs.2,011 Cr remains a risk. Management's H2-weighted margin guidance of 18.5-20% requires meaningful US launch contributions to be achieved.
Key Investment Insights
Key Positives
- Revenue recovered 8.84% QoQ from Q4 FY26 trough, driven by seasonal pattern and initial new launch contribution.
- EBITDA margin improved sequentially from 15.24% to 16.75%, in line with H2-weighted guidance trajectory.
- Standalone PAT grew 124.15% QoQ to Rs.862.16 Cr, recovering from the Q4 FY26 trough which included a Rs.31 Cr associate impairment.
- No exceptional items were recorded in Q1 FY27, versus a Rs.275.91 Cr charge in FY26.
- New subsidiaries incorporated (CiplaRna GmbH, Cipla Middle East, Aspergen) for future growth.
Risk Factors
- EBITDA margin compressed 881 bps YoY to 16.75%, driven by material cost (+626 bps) and employee cost (+217 bps) inflation.
- Consolidated PAT declined 39.19% YoY to Rs.789.05 Cr, with earnings lagging revenue growth.
- Total material cost ratio surged to 37.46% of revenue from 31.20% a year ago, reflecting API cost inflation and Ventolin inventory build.
- Employee benefits expense grew 14.11% YoY, absorbing 217 bps more of revenue, indicating structural cost pressure.
- NPPA litigation contingent liability of Rs.2,011 Cr remains unresolved, with no provision made.
- US generics business continues to face Revlimid erosion and Lanreotide supply disruption, dragging consolidated profitability.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.